NO20074448L - Thiazolidinones for use as inhibitors of polo-like kinase (PLK) - Google Patents

Thiazolidinones for use as inhibitors of polo-like kinase (PLK)

Info

Publication number
NO20074448L
NO20074448L NO20074448A NO20074448A NO20074448L NO 20074448 L NO20074448 L NO 20074448L NO 20074448 A NO20074448 A NO 20074448A NO 20074448 A NO20074448 A NO 20074448A NO 20074448 L NO20074448 L NO 20074448L
Authority
NO
Norway
Prior art keywords
polo
kinase
inhibitors
thiazolidinones
plk
Prior art date
Application number
NO20074448A
Other languages
Norwegian (no)
Inventor
Holger Hess-Stumpp
Dirk Kosemund
Gerhard Siemeister
Olaf Prien
Knut Eis
Lars Wortmann
Damian Arnaiz
Volker Schulze
Uwe Eberspacher
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102005005395A external-priority patent/DE102005005395A1/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20074448L publication Critical patent/NO20074448L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen vedrører tiazoli-dinonene med generell formel (I) fremstillingen og anvendelsen derav som inhibitorer av pololignende kinase (Plk) for anvendelse ved behandlingen av forskjellige sykdommer.This invention relates to the thiazole dinones of general formula (I) preparation and use thereof as inhibitors of polo-like kinase (P1k) for use in the treatment of various diseases.

NO20074448A 2005-02-03 2007-08-31 Thiazolidinones for use as inhibitors of polo-like kinase (PLK) NO20074448L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005005395A DE102005005395A1 (en) 2005-02-03 2005-02-03 New thiazolidinone compounds are polo-like kinase inhibitors, useful for treating e.g. cancer, autoimmune diseases, cardiovascular diseases, infectious diseases, nephrological diseases and viral diseases
US65123205P 2005-02-10 2005-02-10
PCT/EP2006/001037 WO2006082107A1 (en) 2005-02-03 2006-02-02 Thiazolidinones for use as inhibitors of polo-like kinase (plk)

Publications (1)

Publication Number Publication Date
NO20074448L true NO20074448L (en) 2007-10-31

Family

ID=38481436

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074448A NO20074448L (en) 2005-02-03 2007-08-31 Thiazolidinones for use as inhibitors of polo-like kinase (PLK)

Country Status (4)

Country Link
KR (1) KR20070100830A (en)
CR (1) CR9323A (en)
IL (1) IL185023A0 (en)
NO (1) NO20074448L (en)

Also Published As

Publication number Publication date
KR20070100830A (en) 2007-10-11
CR9323A (en) 2008-02-21
IL185023A0 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
NO20090628L (en) Pyridizinone derivatives
NO20080675L (en) P38-Map kinase inhibitors and methods for their use
NO20076059L (en) 2,4-Diamino-pyrimidines used as aurora inhibitors
NO20081482L (en) Delta and epsilon crystal forms for imatinib mesylate
NO20082594L (en) Pyrimidinylbenzotiofenforbindelser
NO20073791L (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
NO20073631L (en) Metasubstituted thiazolidinones, processes for the preparation and use thereof as drugs
NO20070933L (en) Indazoles useful in the treatment of cardiovascular diseases
ATE542823T1 (en) 4,5-DIHYDRO-Ä1,2,4ÜTRIAZOLOÄ4,3-FÜPTERIDINE AS A PLK1 PROTEIN KINASE INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE DISEASES
NO20065847L (en) Diphenylimidazopyrimidines and imidazolamines as inhibitors of B-secretase
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
NO20082026L (en) Deazapurins useful as inhibitors of Janus kinases
NO20082090L (en) Pyridopyrimidinone inhibitors of P13K alpha
NO20073859L (en) Pyrrolopyrazoles, potent kinase inhibitors
EA200900136A1 (en) PYRROPHYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
NO20081729L (en) New diazaspiroalkanes and their use in the treatment of CCR8-mediated diseases
NO20084652L (en) Deazapurins useful as inhibitors of januskinases
NO20082496L (en) pyrazine derivatives
NO20084418L (en) Azolopyridin-3-one derivatives as inhibitors of endothelial lipase
NO20081217L (en) New benzothiazole derivatives
NO20075113L (en) protein kinase inhibitors
NO20063761L (en) Sulfonamide derivatives for the treatment of diseases
MX2009002239A (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application